FGFR1 Amplification as A Predictor of Efficacy in A Biomarker-Driven Phase II Study of BIBF 1120 in Advanced Squamous Cell Lung Cancer Patients Who Have Failed Up to Two Prior Chemotherapeutic Regimens
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2017
Price : $35 *
At a glance
- Drugs Nintedanib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 12 Jun 2017 Last checked against ClinicalTrials.gov record.
- 10 May 2017 Status changed from active, no longer recruiting to completed.